

## TITLE PAGE

**Title:** *Protective lipid-lowering genetic variants in healthy older individuals without coronary heart disease*

**Running title:** *Lacaze - Protective lipid-lowering variants*

**Authors:** Paul Lacaze, PhD<sup>1\*</sup>, Moeen Riaz, PhD<sup>1</sup>, Robert Sebra, PhD<sup>2</sup>, Amanda J Hooper, PhD<sup>3,4</sup>, Jing Pang, PhD<sup>3</sup>, Jane Tiller, LLB, MSc GenCoun<sup>1</sup>, Galina Polekhina, PhD<sup>1</sup>, Andrew M Tonkin, PhD<sup>1</sup>, Christopher M Reid, PhD<sup>1,5</sup>, Sophia Zoungas, MD, PhD<sup>1</sup>, Anne M Murray, MD, MSc<sup>6</sup>, Stephen J Nicholls MD, PhD<sup>7</sup>, Gerald F Watts, MD, PhD<sup>4,8</sup>, Eric Schadt, PhD<sup>2</sup> & John J McNeil, MD, PhD<sup>1</sup>

### Departments and institutions:

<sup>1</sup> Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

<sup>2</sup> Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, USA.

<sup>3</sup> School of Medicine, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Australia

<sup>4</sup> Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, Western Australia, Australia.

<sup>5</sup> School of Public Health, Curtin University, Perth, WA, Australia

<sup>6</sup> Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, MN, USA

<sup>7</sup> Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Clayton, Victoria, Australia;

<sup>8</sup>Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia.

**Corresponding author:**

\*Paul Lacaze, PhD. [paul.lacaze@monash.edu](mailto:paul.lacaze@monash.edu)

Department of Epidemiology and Preventive Medicine,

School of Public Health and Preventive Medicine

Monash University, Level 5, The Alfred Centre

99 Commercial Road, Melbourne VIC 3004, Australia.

Ph. +61 3 9903 0412, Fax: +61 3 9903 0556

ORCID ID: 0000-0002-0902-6798

**Manuscript word count:** 4677

**Subject Terms:** Genetics, Aging, Coronary Artery Disease, Lipids and Cholesterol

## ABSTRACT

**Background:** Disruptive genetic variants in the *PCSK9* and *APOB* genes result in lower serum low-density lipoprotein cholesterol (LDL-C) levels and confer protection against coronary heart disease (CHD). Few studies have measured the prevalence and selective advantage of such variants among healthy older individuals without prior CHD events.

**Methods and Results:** We performed targeted sequencing of the *PCSK9* and *APOB* genes in 13,131 healthy older individuals without CHD aged 70 years or older enrolled into the ASPirin in Reducing Events in the Elderly (ASPREE) trial. We detected predicted loss-of-function (pLoF) variants in the *PCSK9* and *APOB* genes, and associated variant carrier status with blood lipid levels. We detected 22 different rare *PCSK9/APOB* candidate variants with lipid-lowering effect, carried by 104 participants (carrier rate 1 in 126). Rare variant carrier status was associated with 19.4 mg/dl (14.6%) lower LDL-C, compared with non-carriers ( $P < 0.001$ , adjusted for statin use). Statin prescriptions were less prevalent in rare variant carriers (16%) than non-carriers (35%). The *PCSK9* R46L variant (rs11591147-T) was associated with 15.5mg/dl (11.8%) lower LDL-C in heterozygotes, and 25.2 mg/dl (19.2%) lower LDL-C in homozygotes, respectively (both  $P < 0.001$ ).

**Conclusions:** Lipid-lowering genetic variants are carried by healthy older individuals and contribute to CHD-free survival.

**Keywords:** Genetics, lipids, cholesterol, coronary heart disease, familial hypercholesterolemia

## 1 INTRODUCTION

2 Genetic variants that lower serum low-density lipoprotein cholesterol (LDL-C) levels have been  
3 demonstrated to be protective against coronary heart disease (CHD) <sup>1-9</sup>. In particular, protection  
4 can be conferred by rare loss-of-function, protein-truncating variants in canonical lipid-  
5 metabolism genes, including the apolipoprotein B (*APOB*) <sup>3</sup> and proprotein convertase subtilisin  
6 kexin type 9 (*PCSK9*) <sup>3,10</sup> genes. These protective genetic variants tend to be rare in the  
7 population. In addition, LDL-C particle size and other lipoprotein-related genotypes have been  
8 associated with CHD-free longevity <sup>11</sup>.

9 Familial hypobetalipoproteinemia is caused by heterozygosity for *APOB* variants that generally  
10 result in LDL-C concentrations that are >50% lower than normal, while *PCSK9* loss-of-function  
11 variants are associated with more modest effects of 15-40% lower LDL-C <sup>12</sup>. Discovery and  
12 understanding of rare protective variants in these genes, particularly *PCSK9*, has informed the  
13 successful development of several lipid-lowering therapies <sup>13</sup>. However, most cholesterol-  
14 lowering variants, to date, have been identified from case-control or population-based studies <sup>1-9</sup>.  
15 Healthy older populations without CHD represent an under-studied resource for the discovery  
16 and understanding of protective lipid-modifying genetic variants that may reduce CHD risk.

17 With this rationale, we sequenced 13,131 healthy older individuals without CHD enrolled in the  
18 ASPirin in Reducing Events in the Elderly (ASPREE) trial <sup>14</sup>, with average age 75 years. Among  
19 this healthy older CHD-free population, we measured the prevalence of rare cholesterol-lowering  
20 variants in canonical lipid metabolism genes *PCSK9* and *APOB*, and associated variant carrier  
21 status with serum LDL-C and total cholesterol (TC) levels.

## 22 **METHODS**

### 23 **Study population**

24 Participants were enrolled in the ASPREE study, a randomized, placebo-controlled trial of  
25 daily low-dose aspirin<sup>15-17</sup>. The ASPREE study design<sup>18,19</sup>, recruitment<sup>20</sup>, and baseline  
26 characteristics<sup>14</sup> have been published previously. Participants had no previous diagnosis of  
27 atherosclerotic or atherothrombotic cardiovascular disease, including myocardial infarction;  
28 heart failure; angina; pectoris; stroke, or transient ischemic attack; or diagnosis of atrial  
29 fibrillation or high blood pressure<sup>21</sup>. Diagnosis of dementia or other serious illness likely to  
30 cause death within 5 years were also exclusion criteria. Genetic analysis was conducted on  
31 13,131 samples provided by Australian ASPREE participants aged 70 years or older at  
32 enrolment<sup>22</sup>. Ethics approval for genetic analysis was obtained from the Alfred Hospital  
33 Human Research Ethics Committee.

### 34 **DNA sequencing and variant analysis**

35 A targeted sequencing panel was designed containing the *PCSK9* and *APOB* genes<sup>22</sup>.  
36 Following standard protocols, DNA was extracted and sequenced using the Thermo Fisher  
37 Scientific S5TM XL system to average 200X depth, with sequences aligned to the human  
38 genome reference<sup>37</sup>. We identified candidate cholesterol-lowering variants from sequence  
39 data using two methods: 1) prediction of rare candidate loss-of-function, protein-truncating  
40 *PCSK9* and *APOB* variants using the Loss-Of-Function Transcript Effect Estimator (LoFTEE)  
41 tool, high-confidence filter, a plugin of Ensemble Variant Effect Predictor (VEP)<sup>23</sup>; and 2)  
42 assessment of candidate variants associated with hypercholesterolaemia or  
43 hypobetalipoproteinaemia identified from published functional and population studies<sup>3,10,24</sup>  
44 (for list of variants meeting the inclusion criteria, see Supplementary Materials). We also  
45 examined the effect of the *PCSK9* R46L variant with known lipid-lowering effect (rs11591147-  
46 T)<sup>25</sup>. Variants were curated manually by two or more laboratory scientists following

47 ACMG/AMP Standards <sup>26</sup> and variant classification was agnostic to lipid effects. A random  
48 selection of 10% of variants detected were validated using Sanger sequencing with 100%  
49 concordance.

#### 50 **Association of variant carrier status with blood lipid levels**

51 We sought to determine whether *PCSK9/APOB* rare variant carriers in ASPREE were associated  
52 with lower serum cholesterol levels at time of enrolment, versus age- and gender-matched non-  
53 carriers. To do this, we compared serum LDL-C and total cholesterol (TC) levels between  
54 variant carriers and N=9,540 age- and gender-matched non-carrier ASPREE controls who did  
55 not carry any *PCSK9* or *APOB* variants that met our inclusion criteria. Baseline LDL-C and TC  
56 levels were measured in routine blood samples provided by ASPREE participants at enrolment,  
57 analysed at commercial pathology laboratories. We tested association of variant carrier status  
58 with serum LDL-C and TC levels using multivariable linear regression, adjusting for age,  
59 gender, diabetes, hypertension, smoking status, alcohol use, and body mass index. We first tested  
60 association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then  
61 separately using statin-adjusted levels, dividing by LDL-C and TC levels by 0.7 and 0.8  
62 respectively for those using statin medication to estimate untreated levels, as done previously <sup>3</sup>.  
63 We identified statin users based on concomitant medication data collected by ASPREE  
64 (Anatomical Therapeutic Chemical [ATC] code = C10, lipid modifying agents).

## 65 RESULTS

66 Characteristics of the 13,131 sequenced participants are shown in Table 1. The median age at  
67 enrolment was 75 years; with 54% of participants female; 28% obese; and 4% current smokers.  
68 Participants had no previous diagnosis of cardiovascular disease or dementia<sup>14</sup>. Most  
69 participants were of European ancestry (99% self-reported as white/Caucasian).

70 Among this population, we detected a total of 104 ASPREE participants carrying rare candidate  
71 loss-of-function (LoF) variants that met our inclusion criteria ( $MAF < 0.01$ ). This corresponded to  
72 a carrier rate of 1 in 126 participants. We detected a total of 22 different rare variants, ranging in  
73 frequency between  $MAF = 0.00335$  (detected in 44 ASPREE participants) to  $MAF = 0.00008$   
74 (singletons detected in only one ASPREE participant) (Table 2). We found six putatively novel  
75 rare *APOB* variants that, at the time of our analysis, were not found in the gnomAD or dbSNP  
76 databases, and were not previously reported in the literature. Each of these rare *APOB* variants  
77 were detected as singletons in the ASPREE cohort ( $MAF = 0.0008$ ) and met our criteria for loss-  
78 of-function (Table 2).

79 Based on raw LDL-C and TC levels uncorrected for statin use, rare variant heterozygous carrier  
80 status in ASPREE (N=104 participants) was associated with 11.6 mg/dl (9.7%) lower serum  
81 LDL-C ( $P < 0.001$ ) and 7.8 mg/dl (3.9%) lower serum TC ( $P < 0.001$ ), versus non-carriers,  
82 adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use, and BMI (Table 3).

83 After adjusting for statin use (dividing LDL-C and TC levels by 0.7 and 0.8 respectively for  
84 those taking statin medication), rare variant heterozygous carrier status was associated with 19.4  
85 mg/dl (14.6%) lower adjusted serum LDL-C ( $P < 0.001$ ) and 16.4mg/dl (7.5%) lower adjusted  
86 serum TC ( $P < 0.001$ ), versus non-carriers. The prevalence of lipid-lowering statin prescriptions  
87 among rare variant carriers was 16% (N=17/104), less than half that observed in non-carriers  
88 (35%, N=3324/9540).

89 The estimated median untreated LDL-C level in non-carriers was 131.5 mg/dl (110.4 to 154.7),  
90 compared with 112.1 mg/dl (92.8 to 139.2) in rare *PCSK9/APOB* variant carriers. At the per-  
91 gene level, rare variant carrier status for *PCSK9* and *APOB* variants separately was also  
92 associated with significantly lower LDL-C levels for both genes ( $P < 0.001$ ) (Figure 1).

93 For the more common *PCSK9* R46L variant (rs11591147-T, ASPREE MAF=0.03541),  
94 heterozygous and homozygous carrier status were associated with 15.5mg/dl (11.8%) lower and  
95 25.2 mg/dl (19.2%) lower statin-corrected LDL-C levels respectively ( $P = < 0.001$ ) (Table 3).



## 96 DISCUSSION

97 In this study, we identified rare *PCSK9* and *APOB* variants that that lower serum LDL-  
98 cholesterol levels among a population of healthy older individuals without a prior history of  
99 CHD events. Variant carrier status was associated with significantly lower serum LDL-C and TC  
100 concentrations, using statin-corrected or uncorrected levels. The prevalence of statin  
101 prescriptions in variant carriers were less than half that observed in non-carriers. Together, these  
102 results indicate that lipid-lowering genetic variants are carried by healthy elderly individuals  
103 without CHD, and play an important role in coronary disease-free survival throughout the human  
104 lifespan.

105 Consistent with other studies <sup>1-9</sup>, we observed that loss-of-function variants in *PCSK9* and *APOB*  
106 lower serum LDL-C concentrations. However, to our knowledge, the prevalence shown in  
107 ASPREE during ageing free of atherosclerotic cardiovascular disease manifestations has not  
108 previously been demonstrated. Variants analysed were found to lower serum LDL-C and TC  
109 levels among the ASPREE population, with the difference in LDL-C concentrations between  
110 ASPREE rare variant carrier and non-carriers being ~20 mg/dl after adjusting for statin use. At  
111 an average participant age of 75 years, this represents the effect of potentially a lifetime of  
112 exposure to genetically-determined lower LDL-C.

113 Meta-analysis of statin trials suggests for a 38 mg/dl reduction in LDL-C, there is a 20-22%  
114 reduction in CHD risk, in the setting of relatively short clinical trials <sup>27</sup>. Mendelian  
115 randomisation studies, however, demonstrate the importance of lifetime exposure to low LDL-C,  
116 suggesting that genetically-determined low LDL-C is associated with a greater magnitude of  
117 CHD risk-reduction, compared with equivalent reduction through statin use <sup>28</sup>. It is therefore  
118 likely that ASPREE rare variant carriers detected in this study, who have experienced a lifetime  
119 of exposure to genetically lower LDL-C, have benefited substantially from lower CHD risk.

120 However, it is noteworthy that the rare variants detected likely account for only a fraction of the  
121 reduced CHD risk in the ASPREE population (N=13,131), with a range of other genetic and  
122 lifestyle factors contributing.

123 Strengths of the study include the sample size and unique ascertainment of the ASPREE  
124 population. The sequenced cohort was comprised of 13,131 individuals with an average age of  
125 75 years, with no previous diagnosis of CHD or other cardiovascular events. It is rare for a  
126 population ascertained with these characteristics to be made available for genetic analysis. The  
127 sequenced cohort was the result of a unique set of circumstances made possible by the strict  
128 ASPREE inclusion criteria and age cut-off, and associated research biobank <sup>14,29</sup>.

129 Another strength of the study is that ASPREE participants were well characterised, each  
130 receiving a medical assessment by a general practitioner at enrolment, to confirm eligibility for  
131 the trial, and to rule out previous diagnoses of CHD <sup>14</sup>. This provided confidence that detected  
132 variant carriers were CHD event-free at enrolment. Other strengths of the study include the depth  
133 of sequencing, focus on canonical lipid metabolism genes with established biological effect, and  
134 stringency of variant curation used, to ensure only high-confidence variants were included in  
135 analyses.

136 Limitations of the study include our results not necessarily being generalizable to populations of  
137 non-European ancestry. Further, we caution the comparison of rare variant prevalence between  
138 ASPREE and reference populations such as gnomAD, due to the potential for technical artefacts  
139 introduced by differences in sequencing technologies and variant curation, and population  
140 stratification related to differences in genetic ancestry. These well-known sources of variability  
141 are compounded when attempting to compare rare variant frequencies between studies <sup>30</sup>.  
142 Nonetheless, our results suggest that rare *PSCK9/APOB* variants are enriched in healthy older

143 CHD-free individuals (Table 2), consistent with previous studies showing that LDL-C-lowering  
144 variants are associated with reduced risk for CHD and longevity<sup>1-9</sup>.

145 Regarding the genes analysed in our study, we focused on only the most established two  
146 canonical lipid metabolism genes where rare loss-of-function variants have been demonstrated to  
147 have a high effect in reducing LDL-C levels (*PCSK9* and *APOB*)<sup>1,3,8,9</sup>. We did not examine  
148 gain-of-function variants in the *LDLR* gene, or loss-of-function variants in other genes that have  
149 been associated with LDL-C reduction (e.g. *NPC1L1*, *LPA*, *APOC3*, *ANGPTL3/4*, and *ASGR1*).  
150 These additional genes were not included on the sequencing panel used. We also could not  
151 calculate polygenic scores due to the targeted nature of the sequencing assay.

152 We did not functionally validate the detected rare variants, and we were unable to estimate the  
153 degree to which each individual rare variant was associated with lower serum LDL-C levels. The  
154 relatively low number of rare variants detected necessitated combining rare variants together into  
155 a single group for blood lipid associations. A further limitation of our study was the lack of  
156 assessment of subclinical atherosclerosis in the ASPREE trial, including the absence of data on  
157 coronary artery calcium (CAC) and carotid intima-media thickness.

## 158 **CONCLUSIONS**

159 Cholesterol-lowering *PCSK9* and *APOB* variants are carried by healthy older CHD-free  
160 individuals. Our study demonstrates the unique contribution of healthy elderly populations to  
161 exploring genetic determinants of health and lifespan. Historically, healthy elderly populations  
162 have not been the focus of large human genetic studies, mainly due to the difficulties in  
163 ascertaining large numbers of samples in this age group. However, studies focused on the  
164 healthy elderly represent an under-explored opportunity for detection of novel protective  
165 variants, especially in the context of lipid regulation and CHD<sup>29</sup>. The ASPREE population, in

166 particular, provides an exceptional platform, with a unique age and CHD-free ascertainment  
167 profile.

168 **Acknowledgements:** We thank the ASPREE trial staff in Australia and the United States, the  
169 ASPREE participants who volunteered for the trial, and the general practitioners and staff of the  
170 medical clinics who cared for the participants.

171 **Funding sources:** The ASPREE Healthy Ageing Biobank is supported by a Flagship cluster  
172 grant (including the Commonwealth Scientific and Industrial Research Organisation, Monash  
173 University, Menzies Research Institute, Australian National University, University of  
174 Melbourne); and grants (U01AG029824) from the National Institute on Aging and the National  
175 Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the  
176 National Health and Medical Research Council of Australia, and by Monash University and the  
177 Victorian Cancer Agency. P.L is supported by a National Heart Foundation Future Leader  
178 Fellowship (102604).

179 **Disclosures:** Watts has received honoraria and/or research grants from Arrowhead, AstraZeneca,  
180 Kowa, Regeneron, Sanofi, Amgen, and Novartis. Nicholls has received research support and/or  
181 honoraria for Amgen, AstraZeneca, Eli Lilly, Esperion, Novartis, Merck, Pfizer, Iowa and  
182 Sanofi-Regeneron. Sebra serves as Vice-President of Technology Development at Sema4.  
183 Schadt serves as Chief Executive Officer at Sema4. No other conflicts were reported.

184 **Ethics approval and patient consent statement:** Ethics approval for genetic analysis was  
185 obtained from the Alfred Hospital Human Research Ethics Committee. All participants provided  
186 informed consent for genetic analysis.

187 **Data availability statement:** Data are available from the corresponding author upon request.

## 188     **References**

- 189     1.     Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and  
190     protection against coronary heart disease. *N Engl J Med*. 2006;354(12):1264-1272.
- 191     2.     Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating Variants in ANGPTL4 and Risk of  
192     Coronary Artery Disease. *N Engl J Med*. 2016;374(12):1123-1133.
- 193     3.     Peloso GM, Nomura A, Khera AV, et al. Rare Protein-Truncating Variants in APOB, Lower Low-  
194     Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. *Circ Genom  
195     Precis Med*. 2019;12(5):e002376.
- 196     4.     Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of  
197     Cardiovascular Disease and Diabetes. *The New England journal of medicine*. 2016;375(22):2144-  
198     2153.
- 199     5.     Nomura A, Won HH, Khera AV, et al. Protein-Truncating Variants at the Cholesteryl Ester  
200     Transfer Protein Gene and Risk for Coronary Heart Disease. *Circ Res*. 2017;121(1):81-88.
- 201     6.     Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and  
202     LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA*. 2019;321(4):364-373.
- 203     7.     Ye H, Zhao Q, Huang Y, et al. Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671  
204     polymorphism and coronary heart disease. *Biomed Res Int*. 2014;2014:564940.
- 205     8.     Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. *Clin  
206     Biochem Rev*. 2008;29(1):11-26.
- 207     9.     Rimbert A, Pichelin M, Lecoq S, et al. Identification of novel APOB mutations by targeted next-  
208     generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.  
209     *Atherosclerosis*. 2016;250:52-56.
- 210     10.    Dron JS, Hegele RA. Complexity of mechanisms among human proprotein convertase subtilisin-  
211     kexin type 9 variants. *Curr Opin Lipidol*. 2017;28(2):161-169.
- 212     11.    Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated  
213     with exceptional longevity. *JAMA*. 2003;290(15):2030-2040.
- 214     12.    Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. *Curr Opin Lipidol*.  
215     2014;25(3):161-168.
- 216     13.    Graham I, Shear C, De Graeff P, et al. New strategies for the development of lipid-lowering  
217     therapies to reduce cardiovascular risk. *Eur Heart J Cardiovasc Pharmacother*. 2018;4(2):119-  
218     127.
- 219     14.    McNeil JJ, Woods RL, Nelson MR, et al. Baseline Characteristics of Participants in the ASPREE  
220     (ASpirin in Reducing Events in the Elderly) Study. *J Gerontol A Biol Sci Med Sci*.  
221     2017;72(11):1586-1593.
- 222     15.    McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in  
223     the Healthy Elderly. *N Engl J Med*. 2018;379(16):1509-1518.
- 224     16.    McNeil JJ, Woods RL, Nelson MR, et al. Effect of Aspirin on Disability-free Survival in the Healthy  
225     Elderly. *N Engl J Med*. 2018;379(16):1499-1508.
- 226     17.    McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy  
227     Elderly. *N Engl J Med*. 2018;379(16):1519-1528.
- 228     18.    Group AI. Study design of ASPIrin in Reducing Events in the Elderly (ASPREE): a randomized,  
229     controlled trial. *Contemporary clinical trials*. 2013;36(2):555-564.
- 230     19.    Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-  
231     dose aspirin for major adverse cardiovascular events in older people in Australia: results from  
232     the ASPIrin in Reducing Events in the Elderly (ASPREE) pilot study. *Med J Aust*. 2008;189(2):105-  
233     109.
- 234     20.    Lockery JE, Collyer TA, Abhayaratna WP, et al. Recruiting general practice patients for large  
235     clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study. *Med J  
236     Aust*. 2019;210(4):168-173.

- 237 21. Lacaze P, Sebra R, Riaz M, et al. Familial Hypercholesterolemia in a Healthy Elderly Population.  
238 *Circ Genom Precis Med.* 2020.
- 239 22. Lacaze P, Sebra R, Riaz M, et al. Medically actionable pathogenic variants in a population of  
240 13,131 healthy elderly individuals. *Genet Med.* 2020.
- 241 23. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706  
242 humans. *Nature.* 2016;536(7616):285-291.
- 243 24. Elbitar S, Susan-Resiga D, Ghaleb Y, et al. New Sequencing technologies help revealing  
244 unexpected mutations in Autosomal Dominant Hypercholesterolemia. *Sci Rep.* 2018;8(1):1943.
- 245 25. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density  
246 lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and  
247 meta-analyses. *J Am Coll Cardiol.* 2010;55(25):2833-2842.
- 248 26. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence  
249 variants: a joint consensus recommendation of the American College of Medical Genetics and  
250 Genomics and the Association for Molecular Pathology. *Genetics in medicine : official journal of  
251 the American College of Medical Genetics.* 2015;17(5):405-424.
- 252 27. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL  
253 cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of  
254 individual data from 27 randomised trials. *Lancet.* 2012;380(9841):581-590.
- 255 28. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein  
256 cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian  
257 randomization analysis. *J Am Coll Cardiol.* 2012;60(25):2631-2639.
- 258 29. Lacaze P, Woods R, Zoungas S, et al. The genomic potential of the Aspirin in Reducing Events in  
259 the Elderly and Statins in Reducing Events in the Elderly studies. *Intern Med J.* 2017;47(4):461-  
260 463.
- 261 30. Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study designs and  
262 statistical tests. *Am J Hum Genet.* 2014;95(1):5-23.

263

264 **Table 1. Characteristics of Sequenced Participants at Enrolment.** Sequenced participants  
265 were enrolled in the ASPREE clinical trial, aged 70 years and older (average age 75 years),  
266 without a previous diagnosis of cardiovascular disease, dementia, permanent physical disability,  
267 or current diagnosis of life-threatening cancer at enrolment. Most were white/Caucasian and 54%  
268 were female.

	<b>ASPREE</b> <b>N=13,131</b> (mean age 75 years)
<b>Female sex</b> – no. (%)	7056 (54)
<b>Age in years</b> – no. (%)	
70-74 yr	7,894 (60)
75-79 yr	3,406 (26)
≥80 yr	1,831 (14)
<b>Race or ethnic group</b> <sup>a</sup> – no. (%)	
White/Caucasian	12,953 (99)
Other	178 (1)
Obese (BMI≥30 kg/m <sup>2</sup> ) <sup>b</sup> (%)	28
Current smoking (%)	4
Statin use <sup>c</sup> (%)	33
Heart, stroke or vascular disease <sup>d</sup> (%)	0

<sup>a</sup> Self-report.

<sup>b</sup> Obese was defined as body-mass index (weight in kilograms divided by the square of the height in meters) of ≥30.

<sup>c</sup> Anatomical Therapeutic Chemical (ATC) code C10 (lipid modifying agents).

<sup>d</sup> Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study<sup>14</sup>



**Table 2: Prevalence of LDL cholesterol-lowering variants in a healthy elderly CHD-free population (ASPREE).** We sequenced N=13,131 individuals aged 70 years and older to detect cholesterol-lowering variants using two methods: 1) prediction of rare candidate loss-of-function, protein-truncating *PCSK9* and *APOB* variants; and 2) assessment of candidate variants identified in previously published functional or population studies. We also examined the effect of the common *PCSK9* R46L variant with lipid-lowering effect; rs11591147<sup>25</sup>. Variants were curated following ACMG/AMP Standards<sup>26</sup>.

Gene	Variant (GRCh37)	rsID	Type	Consequence	ASPREE Carriers	ASPREE MAF	gnomAD-NFE MAF
						N=13,131	N=64,603
<b>RARE VARIANTS (MAF&lt;0.01)</b>							
<i>PCSK9</i>	NM_174936.3(PCSK9): c.709C>T (p.Arg237Trp)	rs148195424	SNV	Missense	44	0.00335	0.00093
<i>PCSK9</i>	NM_174936.3(PCSK9): c.1327G>A(p.Ala443Thr)	rs28362263	SNV	Missense	13	0.00099	0.00029
<i>PCSK9</i>	NM_174936.3(PCSK9): c.657+1G>T	rs142824171	SNV	Splice donor	7	0.00053	0.00007
<i>PCSK9</i>	NM_174936.3(PCSK9): c.1384T>C (p.Ser462Pro)	rs746115963	SNV	Missense	7	0.00053	0.00012
<i>PCSK9</i>	NM_174936.3(PCSK9): c.520C>T (p.Pro174Ser)	rs533273863	SNV	Missense	5	0.00038	0.00008
<i>PCSK9</i>	NM_174936.3(PCSK9): c.1863+1G>A	rs765335983	SNV	Splice donor	5	0.00038	0.00003
<i>PCSK9</i>	NM_174936.3(PCSK9): c.277C>T (p.Arg93Cys)	rs151193009	SNV	Missense	3	0.00023	0.00002
<i>PCSK9</i>	NM_174936.3(PCSK9): c.341T>C (p.Val114Ala)	rs775988212	SNV	Missense	2	0.00015	0.00003
<i>PCSK9</i>	NM_174936.3(PCSK9): c.471C>A (p.Asn157Lys)	rs143117125	SNV	Missense	2	0.00015	0.00005
<i>PCSK9</i>	NM_174936.3(PCSK9): c.1300C>T(p.Arg434Trp)	rs757143429	SNV	Missense	2	0.00015	0.00001
<i>PCSK9</i>	NM_174936.3(PCSK9): c.313C>T (p.Arg105Trp)	rs747072726	SNV	Missense	1	0.00008*	0.00002
<i>PCSK9</i>	NM_174936.3(PCSK9): c.706G>A (p.Gly236Ser)	rs149489325	SNV	Missense	1	0.00008*	0.00005
<i>PCSK9</i>	NM_174936.3(PCSK9): c.658-2A>C	rs371336612	SNV	Splice acceptor	1	0.00008*	-
<b>TOTAL</b>					<b>92</b>		
<i>APOB</i>	NM_000384.3(APOB): c.6253C>T(p.Arg2085Ter)	rs121918386	SNV	Stop gained	3	0.00023	0.00004
<i>APOB</i>	NM_000384.3(APOB): c.4503T>G (p.Tyr1501Ter)	rs368825685	SNV	Stop gained	1	0.00008*	0.00001
<i>APOB</i>	NM_000384.3(APOB): c.1315C>T (p.Arg439Ter)	rs142066904	SNV	Stop gained	1	0.00008*	0.00003
<i>APOB</i>	NM_000384.2(APOB): c.11153C>G (Ser3718Ter)	-	SNV	Stop gained	1	0.00008*□	-
<i>APOB</i>	NM_000384.2(APOB): c.7300C>T (p.Gln2434Ter)	-	SNV	Stop gained	1	0.00008*□	-
<i>APOB</i>	NM_000384.3(APOB): c.6538C>T (p.Gln2180Ter)	rs1041962	SNV	Stop gained	1	0.00008*□	-
<i>APOB</i>	NM_000384.2(APOB): c.2245-2A>G	-	SNV	Splice acceptor	1	0.00008*□	-

<i>APOB</i>	NM_000384.2( <i>APOB</i> ) 21228615CA>C (deletion)	-	INDEL	Frameshift	1	0.00008 <sup>*□</sup>	-
<i>APOB</i>	NM_000384.2( <i>APOB</i> ) 21230841G>GT (insertion)	-	INDEL	Frameshift	1	0.00008 <sup>*□</sup>	-
<b>TOTAL</b>					<b>11</b>		
<b>PCSK9 R46L (MAF&gt;0.01)</b>							
<i>PCSK9</i>	NM_174936.3( <i>PCSK9</i> ): c.137G>T (p.Arg46Leu)	rs11591147	SNV	Missense			
				HET	465	0.03541	0.01507
				HOMO	6	0.00046	0.0002

SNV = Single nucleotide variant, INDEL = Insertion/deletion, HET = Heterozygote, HOMO = Homozygote, pLoF = Predicted loss of function variant. MAF = Minor allele frequency.

\* Denotes a singleton variant detected in only one ASPREE participant/carrier



□ Denotes a potentially novel protective *APOB* variant not previously described, or found in the gnomAD database<sup>30</sup>

**Table 3. Variant carrier status in ASPREE is associated with reduced serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels.** We compared serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels between variant carriers and N=9,540 non-carrier ASPREE controls. The multivariable linear regression model adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use, and body mass index. We first tested association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then separately using statin-adjusted levels (*adj*LDL-C, *adj*TC), dividing LDL-C and TC levels by 0.7 and 0.8 respectively for those using statin medication to estimate untreated levels, as done previously <sup>3</sup>. We identified statin users based on concomitant medications recorded by ASPREE at baseline. Data are presented as median (inter-quartile range). Statistical significance is denoted by P<0.001. To convert values from mg/dl to mmol/l multiply by 0.02586. ATC code C10 = Anatomical Therapeutic Chemical code C10 (lipid modifying agents).

<b>Rare variant group</b> <i>PCSK9/APOB</i> MAF<0.01	<b>Non-Carriers</b> N=9,540	<b>Heterozygotes</b> N=104	<b>Homozygotes</b> N=0	<b>P-Value</b>
LDL-C (mg/dl)	119.9 (96.7 to 143.1)	108.3 (81.2 to 131.5)	-	<0.001
<i>adj</i> LDL-C (mg/dl)	131.5 (112.1 to 150.8)	112.1 (92.8 to 139.2)	-	<0.001
TC (mg/dl)	201.1 (177.9 to 228.2)	193.3 (170.1 to 220.4)	-	<0.001
<i>adj</i> TC (mg/dl)	217.5 (193.4 to 241.6)	201.1 (177.9 to 225.7)	-	<0.001
<b>Common variant</b> <i>PCSK9</i> rs11591147-T	<b>Non-Carriers</b> N=9,540	<b>Heterozygotes</b> N=465	<b>Homozygotes</b> N=6	<b>P-Value</b>
LDL-C (mg/dl)	119.9 (96.7 to 143.1)	112.1 (88.9 to 131.5)	106.35 (95.7 to 117.0)	<0.001
<i>adj</i> LDL-C (mg/dl)	131.5 (112.1 to 150.8)	116.0 (96.7 to 135.3)	106.4 (95.7 to 117.0)	<0.001
TC (mg/dl)	201.1 (177.9 to 228.2)	197.2 (170.1 to 216.6)	197.2 (168.2 to 211.7)	<0.001
<i>adj</i> TC (mg/dl)	217.5 (193.4 to 241.6)	201.1 (183.6 to 227.1)	197.2 (168.2 to 211.7)	<0.001

**Figure 1. *PCSK9* and *APOB* rare variant carrier status in ASPREE is associated with reduced serum lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels.** Shown is a comparison of LDL-C and TC levels at enrolment for carriers of rare variants (MAF<0.01) in *PCSK9* (N=93) and *APOB* (N=11), compared with non-carrier controls (N=9,540) from ASPREE. Results indicate that rare *APOB/PCSK9* rare variant carrier status is associated with reduced serum LDL-C and TC levels. Linear regression was used to compare statistical differences between groups adjusting for covariates. We first tested association using raw unadjusted LDL-C (**a**) and TC (**b**) levels (not adjusting for statin use), then separately using statin-adjusted *adj*LDL-C (**c**) and *adj*TC (**d**), dividing LDL-C and TC levels by 0.7 and 0.8 respectively for participants using statin medication to estimate untreated levels<sup>3</sup>. Median values are shown as coloured solid lines (magenta and red). We identified statin users based on concomitant medications recorded by ASPREE at baseline. Statistical significance is denoted as \*\*\* P=<0.001. Dyslipidaemia (dotted lines) is defined as serum LDL-C higher than 160 mg/dl, or serum TC higher than 212 mg/dl<sup>14</sup>. To convert values from mg/dl to mmol/l multiply by 0.02586.

### Low-density lipoprotein cholesterol (LDL-C)



### Total cholesterol (TC)

